HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy.

AuthorsJay Y Spiegel, Saurabh Dahiya, Michael D Jain, John Tamaresis, Loretta J Nastoupil, Miriam T Jacobs, Armin Ghobadi, Yi Lin, Matthew Lunning, Lazaros Lekakis, Patrick Reagan, Olalekan Oluwole, Joseph McGuirk, Abhinav Deol, Andre Goy, Khoan Vu, Charalambos Andreadis, Javier Munoz, N Nora Bennani, Julie M Vose, Kathleen A Dorritie, Sattva S Neelapu, Frederick L Locke, Aaron P Rapoport, Brian T Hill, David B Miklos
JournalBlood (Blood) Vol. 137 Issue 13 Pg. 1832-1835 (04 01 2021) ISSN: 1528-0020 [Electronic] United States
PMID33156925 (Publication Type: Letter, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, CD19
  • Biological Products
  • axicabtagene ciloleucel
Topics
  • Antigens, CD19 (therapeutic use)
  • Biological Products
  • Disease Progression
  • Female
  • Humans
  • Immunotherapy, Adoptive
  • Kaplan-Meier Estimate
  • Lymphoma, Large B-Cell, Diffuse (pathology, therapy)
  • Male
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: